News Sentiment

QURE sentiment intelligence

Uniqure NV news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 46.29 Week of 19 Jun 2026
Weighted tone 56/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 61

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

+67.9% over one week, +91.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

UniQure Announces Planned $150 Million Public Offering

Market Reaction

Price moving ahead of tone

65/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 67.9% Price confirming higher
Trend fit Trend active 91.4% over four weeks
Fair value 226.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 41
Negative 7

Relevance

Why the article matched

Direct first
Direct company coverage 61
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
Market source 8
GlobeNewswire 5
simplywall.st 3
Investing.com 3
MT Newswires 2
TradingView 2
Stocktwits 2

Event Lens

What the news is about

Classified themes
Market update 36
Earnings 14
Regulatory and legal 12
Analyst action 4
Guidance 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 68
Stock Titan Direct company coverage

uniQure (QURE) director Jack Kaye sells shares after exercising stock options

uniQure N.V. director Jack Kaye exercised stock options for 5,295 ordinary shares at $31.71 each and subsequently sold all of them in the open market for a weighted average price of $42.57. These transactions, which occurred on June 17, 2026, were conducted under a pre-arranged R

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 12:09
Source
Stock Titan
TradingView Direct company coverage

uniQure reports preliminary AMT-260 Phase I/IIa low-dose results; 3 of 6 patients show 79–100% seizure reduction

uniQure announced preliminary six-month data from its AMT-260 Phase I/IIa trial, revealing that three out of six low-dose patients experienced significant seizure reductions of 79–100%. The treatment was generally well-tolerated, with no serious adverse events reported and no imm

Tone
Positive 76/100
Event
Earnings
Published
22 Jun 2026 11:09
Source
TradingView
TradingView Direct company coverage

QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval

uniQure (QURE) saw its shares jump significantly after the FDA indicated that three-year data from its phase I/II study on AMT-130, a gene therapy for Huntington's disease, could support an accelerated approval BLA. This news provides relief to investors following a previous regu

Tone
Positive 70/100
Event
Regulatory and legal
Published
19 Jun 2026 18:40
Source
TradingView
Stock Titan Direct company coverage

uniQure’s epilepsy gene therapy showed seizure drops in 3 patients

uniQure announced preliminary six-month data from the first, low-dose cohort of its Phase I/IIa trial for AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients showed significant reductions (79%-100%) in disabling seizures, w

Tone
Positive 70/100
Event
Regulatory and legal
Published
19 Jun 2026 11:04
Source
Stock Titan
GlobeNewswire Direct company coverage

uniQure Announces Preliminary Data on the First Cohort in

uniQure announced preliminary six-month data from the first cohort of its Phase I/IIa trial for AMT-260, an investigational gene therapy for refractory mesial temporal lobe epilepsy. Three of six patients in the low-dose cohort experienced significant reductions in seizures, with

Tone
Positive 66/100
Event
Regulatory and legal
Published
19 Jun 2026 11:04
Source
GlobeNewswire
Moomoo Direct company coverage

A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $46 to $70

This article provides an overview of recent analyst ratings for uniQure NV (QURE.US), highlighting that analysts have set price targets ranging from $46 to $70. The consensus among analysts suggests a positive outlook for the company's stock performance.

Tone
Neutral 50/100
Event
Guidance
Published
19 Jun 2026 00:10
Source
Moomoo
Stock Titan Direct company coverage

uniQure N.V. (NASDAQ: QURE) insider sells 164,429 shares across June filings

uniQure N.V. (NASDAQ: QURE) insider Matthew C. Kapusta has reported planned and completed sales of 164,429 ordinary shares across various June filings. This includes recent market sales on June 17 and June 18, 2026, totaling over $7.2 million, as well as scheduled dispositions of

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 21:39
Source
Stock Titan
Barchart.com Direct company coverage

uniQure Stock Looks Drastically Undervalued After Upbeat FDA Meeting

uniQure's stock appears significantly undervalued following a positive meeting with the FDA regarding its Huntington's Disease gene therapy, AMT-130. The FDA's willingness to accept Phase I/II study results for an "accelerated approval" application suggests potential approval, wh

Tone
Positive 73/100
Event
Earnings
Published
18 Jun 2026 17:39
Source
Barchart.com
Investing.com Direct company coverage

uniQure stock rating reiterated at Buy by H.C. Wainwright on FDA update

H.C. Wainwright reiterated a Buy rating and a $50.00 price target for uniQure (NASDAQ:QURE) after a regulatory update from the FDA regarding its Huntington's disease gene therapy, AMT-130. The FDA indicated that the 3-year analysis from the Phase 1/2 trial would be acceptable for

Tone
Positive 85/100
Event
Analyst action
Published
18 Jun 2026 12:39
Source
Investing.com
Stock Titan Direct company coverage

[144] uniQure N.V. SEC Filing

uniQure N.V. filed Form 144 on June 17, 2026, reporting the sale of ordinary shares through Citigroup Global Markets. The filing details the sale of 101,848 shares from vested PSUs/RSUs and 62,581 shares from a stock option exercise, both executed under Rule 10b5-1 plans. These t

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 00:18
Source
Stock Titan
Investing.com Direct company coverage

Mizuho reiterates Outperform on uniQure stock, $35 target

Mizuho has reiterated an Outperform rating and a $35 price target for uniQure (NASDAQ: QURE) following positive developments concerning its gene therapy for Huntington's disease, AMT-130. The FDA has agreed to accept 3-year Phase I/II results for an Accelerated BLA filing and exp

Tone
Positive 73/100
Event
Analyst action
Published
17 Jun 2026 18:18
Source
Investing.com
Investing.com Direct company coverage

Goldman Sachs reiterates Neutral on uniQure stock after FDA meeting

Goldman Sachs has reiterated a Neutral rating and a $46.00 price target for uniQure BV (NASDAQ:QURE) after the company announced plans to file for accelerated approval of its Huntington’s disease gene therapy, AMT-130. The FDA agreed that three-year analysis from the Phase 1/2 st

Tone
Positive 67/100
Event
Analyst action
Published
17 Jun 2026 18:09
Source
Investing.com
CNBC Direct company coverage

UniQure to seek FDA approval for Huntington's disease gene therapy after previous clash with agency

UniQure announced its intention to seek FDA approval for its experimental Huntington's disease gene therapy, following a recent meeting where the FDA indicated that three-year analysis from a Phase 1/2 study would support accelerated approval. This marks a significant reversal fr

Tone
Positive 73/100
Event
Regulatory and legal
Published
17 Jun 2026 18:03
Source
CNBC